ArticleFrontiers in public health2025
Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gammaretrovirus Infections in Humans in the Past, Present, and Future: Have We Defeated the Pathogen?Pathogens (Basel, Switzerland) · 2026Review
- EBV-miR-BART5-3p promotes the proliferation of Burkitt lymphoma cells via glycolytic pathway.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Various subtypes of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, and Burkitt lymphoma, impose a significant global health burden. This study aimed to analyze the severity of these lymphoma types across different global regions from 1990 to 2021, focusing on age-standardized incidence rates, disability-adjusted life years (DALYs), and the Quality of Care Index (QCI). Methods: Data were collected from the Institute for Health Metrics and Evaluation (IHME). Global regions were categorized according to their socio-demographic index (SDI), and trends in death rates, DALYs, and case numbers of various lymphoma subtypes were examined over a 31-year period. The Analysis of Variance (ANOVA) test was employed to compare mortality and DALYs among regions. Results: The analysis revealed significant global and regional trends in lymphoma burden. For Hodgkin lymphoma, DALYs decreased from 0.000513 to 0.000285, and the death rate declined from 0.000629 to 0.000313. In contrast, non-Hodgkin lymphoma exhibited an increase in DALYs from 0.002012 to 0.002430 and in deaths from 0.003182 to 0.003624. Notably, in low SDI regions, a marked increase in DALYs was observed for Hodgkin lymphoma (from 0.000396 to 0.000922) and non-Hodgkin lymphoma (from 0.001147 to 0.002779), with statistical analyses confirming higher mortality rates in these areas. Discussion: These findings highlight significant regional disparities in the severity of lymphoma. While high-income regions demonstrated lower mortality rates due to better healthcare infrastructure, low-income areas experienced higher mortality, underlining the inequality in healthcare access. The results underscore the urgent need for targeted healthcare interventions and specialized treatment strategies to reduce the global lymphoma burden, particularly in under-resourced regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.